3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Non-Muscle Invasive Bladder Neoplasms
6
Urinary Bladder Neoplasms
3
Side Effect of Drug
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Carcinoma in Situ
1
Interventions
Gemcitabine
56
pembrolizumab
50
Cisplatin
43
Magnetic Resonance Spectroscopy
27
enfortumab vedotin
22
Specimen Handling
22
Nivolumab
22
Cystectomy
18
durvalumab
16
Carboplatin
16
avelumab
15
Mitomycin
14
atezolizumab
13
Docetaxel
13
Cystoscopy
12
Fluorouracil
11
Radiation
9
Transurethral Resection of Bladder
8
Radiotherapy
8
Ipilimumab
8
sacituzumab govitecan
7
Standard of Care
7
Radiosurgery
7
Paclitaxel
7
Immunoglobulin G
7
Disulfides
7
erdafitinib
6
cemiplimab
6
Surveys and Questionnaires
6
Surgical Procedures, Operative
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
BCG Vaccine
×
1 year
×
Clear all
NCT06833073
2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2
Recruiting
308 enrolled
NCT05037279
2026-03-20
EVER
Verity Pharmaceuticals Inc.
Phase 3
Recruiting
540 enrolled
NCT04165317
2026-01-22
CREST
Pfizer
Phase 3
Active not recruiting
1,068 enrolled
20 charts